Search This Blog

Wednesday, May 20, 2026

BioMarin Phase 3 trial of VOXZOGO in hypochondroplasia meets primary growth endpoint

 

BioMarin Phase 3 CANOPY-HCH-3 trial of VOXZOGO in hypochondroplasia meets primary growth endpoint with highly significant results

  • BioMarin plans to file an sNDA for VOXZOGO with the FDA in the third quarter of 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)